Propanc Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Propanc Biopharma, Inc. (Delaware corporation) on October 6, 2022, regarding events occurring on that date. The transaction closed on October 12, 2022. The Company is headquartered in Camberwell, Australia, and its securities are not currently registered on a principal U.S. market.
Key Financial Metrics and Transaction Details
- Debt Issuance: Entered into a Securities Purchase Agreement with Red Road Holdings Corporation for a convertible promissory note with a principal amount of $53,750.
- Net Proceeds: The Company received net proceeds of $50,000, intended for general working capital purposes.
- Transaction Costs: The Company paid $3,750 in legal fees and due diligence expenses to the investor.
- Interest Rate: The Note bears interest at 8% per annum, payable in cash or shares of common stock upon maturity or acceleration.
- Liquidity Impact: The filing does not provide current cash balances or total liquidity figures; it only specifies the immediate cash inflow from this specific transaction.
Material Changes and Terms
The primary material change is the creation of a new direct financial obligation. Key terms of the Note include:
- Maturity Date: October 6, 2023.
- Conversion Terms: Convertible into common stock at the option of the investor starting 180 days after issuance. The conversion price is set at 65% of the Market Price (a 35% discount), based on the average of the lowest three trading prices over the ten trading days prior to conversion.
- Conversion Cap: Conversion is restricted if it would cause the investor to beneficially own more than 4.99% of outstanding shares.
- Prepayment Penalties: Prepayment is allowed but subject to escalating premiums ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment within the first 180 days.
- Default Provisions: Upon certain events of default, the outstanding principal and accrued interest increase to 150% of the amount due (the "Default Amount").
Outlook, Risks, and Contingencies
Management intends to use the proceeds for general working capital. The filing highlights several risks and contingencies:
- Dilution Risk: The 35% discount on the conversion price and the potential for interest to be paid in shares may result in significant dilution to existing shareholders.
- Default Risk: Events of default include failure to maintain OTC market listing, failure to comply with SEC reporting requirements, insolvency, or failure to reserve sufficient shares for conversion (at least 5x the issuable amount).
- Penalty Risk: Failure to deliver shares upon conversion within three business days incurs a penalty of $1,000 per day.
- Asset Restrictions: The Company covenants not to sell substantially all assets without investor consent, which could limit strategic flexibility.
Investor Verification Checklist
- Verify the Company's current cash position and ability to service the 8% interest or convert the note without immediate cash outflow.
- Confirm the Company's compliance status with SEC reporting requirements to avoid triggering default events.
- Review the Company's share reserve status to ensure it can meet the covenant of reserving five times the number of shares issuable upon full conversion.
- Assess the potential dilution impact of the 35% discount conversion price on current shareholders.
- Check the Company's listing status on OTC markets to ensure it remains compliant with the Note's covenants.